5,817 Shares in AstraZeneca PLC $AZNCF Bought by Saranac Partners Ltd

Saranac Partners Ltd acquired a new stake in AstraZeneca PLC (OTCMKTS:AZNCF) during the third quarter, according to its most recent filing with the SEC. The firm acquired 5,817 shares of the company’s stock, valued at approximately $876,000.

Separately, Boston Common Asset Management LLC raised its position in AstraZeneca by 5.6% during the 3rd quarter. Boston Common Asset Management LLC now owns 192,589 shares of the company’s stock worth $28,992,000 after buying an additional 10,154 shares during the last quarter. Institutional investors own 40.87% of the company’s stock.

AstraZeneca Stock Performance

AZNCF stock opened at $187.10 on Thursday. AstraZeneca PLC has a one year low of $122.26 and a one year high of $195.00. The company has a fifty day moving average of $186.75 and a 200-day moving average of $176.61.

AstraZeneca Company Profile

AstraZeneca (OTCMKTS:AZNCF) is a global biopharmaceutical company that focuses on the discovery, development, manufacturing and commercialization of prescription medicines. The company’s research and development efforts are concentrated in three main therapeutic areas: oncology; cardiovascular, renal and metabolism; and respiratory, inflammation and autoimmunity. AstraZeneca’s product portfolio includes targeted therapies for lung and breast cancers, novel agents for heart failure and chronic kidney disease, and inhaled treatments for asthma and chronic obstructive pulmonary disease.

The company was formed in 1999 through the merger of Sweden’s Astra AB and the United Kingdom’s Zeneca Group, creating one of the world’s largest pharmaceutical firms.